Interaction of subtilisins with serpins

Protein Science

Volumn 5, Issue 5, 1996, Pages 874-882

  Komiyama, Tomoko ^a   Grøn, Hanne ^a   Pemberton, Philip A ^b   Salvesen, Guy S ^a,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LXR Biotechnology   (United States)

^c BURNHAM INSTITUTE   (United States)

Author keywords

inhibitory mechanism; partition ratio; proteinase inhibitor; serpin; subtilisin

Indexed keywords

SERINE PROTEINASE INHIBITOR; SUBTILISIN;

ARTICLE; COMPLEX FORMATION; CRYSTALLIZATION; ENZYME BINDING; ENZYME INHIBITION; NONHUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE;

EID: 0029874550     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1002/pro.5560050509     Document Type: Article

References (49)

1. 1-proteinase inhibitor with subtilisin BPN'. J Biochem 105:66-71.
2. 1-antitrypsin variant. J Biol Chem 268:24887-24891.
3. Barr PJ. 1991. Mammalian subtilisins: The long-sought dibasic processing endoproieases. Cell 66:1-3.
4. Baugh R, Travis J. 1976. Human leukocyte granule elastase: Rapid isolation and characterization. Biochemistry 15:836-841.
5. 1-proteinase inhibitor and apantichymo-trypsin. J Biol Chem 255:3931-3934.
6. 1 residues. Protein Sci 2:786-799.
7. Bode W, Huber R. 1992. Natural protein proteinase inhibitors and their interaction with proteinases. Eur J Biochem 204:433-451.
8. Brennan SO, Nakayama K. 1994. Furin has the proalbumin substrate specificity and serpin inhibitory properties of an in situ hepatic convertase. FEBS Lett 338:147-151.
9. Carrell RW, Stein PE, Fermi G, Wardell MR. 1994. Biological implications of a 3Å structure of dimeric antithrombin. Curr Struct Biol 2:257-270.
10. Cooperman BS, Stavridi E, Nickbarg E, Rescorla E. 1993. Antichymotrypsin interaction with chymotrypsin. J Biol Chem 265:23616-23625.
11. Dayhoff MO, Barker WC, Hunt LT. 1978. Protein superfamilies. In: Dayhoff MO, ed. Atlas of protein sequence and structure 5. Washington, DC: National Biomedical Research Foundation. pp 9-20.
12. Edelhoch H. 1967. Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 6:1948-1954.
13. 2-antiplasmin. Biochem J 291:933-938.
14. Gettins P, Patston PA, Schapira M. 1992. Structure and mechanism of action of serpins. Hematology/oncology clinics of North America 6:1393-1408.
15. Goldenberg DP. 1989. Analysis of protein conformation by gel electrophoresis. In: Creighton TE, ed. Protein structure: A practical approach. New York: IRL Press. pp 225-250.
16. Greagg MA, Brauer ABE, Leatherbarrow RJ. 1994. Expression and kinetic characterization of barley chymotrypsin inhibitors 1a and 1b. Biochim Biophys Acta 1222:179-186.
17. Grøn H, Breddam K. 1992. Interdependency of the binding subsites in subtilisin. Biochemistry 31:8967-8971.
18. Grøn H, Meldal M, Breddam K. 1992. Extensive comparison of the substrate preferences of two subtilisins as determined with peptide substrates which are based on the principle of intramolecular quenching. Biochemistry 31:6011-6018.
19. 1-proteinase inhibitor variant T345R. Influence of P14 residue on substrate and inhibitory pathways. Biochemistry 33:8538-8547.
20. Jameson GW, Roberts DV, Adams RW, Kyle WSA, Elmore DT. 1973. Determination of the operational molarity of solutions of bovine α-chymotrypsin, trypsin, thrombin and factor Xa by spectrofluorimetric titration. Biochem J 131:107-117.
21. Knight CG. 1986. The characterization of enzyme inhibition. In: Barrett AJ, Salvesen G, eds. Proteinase inhibitors. Amsterdam: Elsevier. pp 23-51.
22. Laskowski M, Kato I. 1980. Protein inhibitors of proteinases. Annu Rev Biochem 49:593-626.
23. Laskowski M, Kato I, Ardelt W, Cook J, Denton A, Empie MW, Kohr WJ, Park SJ, Parks K, Schatzley BL, Schoenberger OL, Tashiro M, Vichot G, Whatley HE, Wieczorek A, Wieczorek M. 1987. Ovomucoid third domain from 100 avian species: Isolation, sequences, and hypervariability of enzyme-inhibitor contact residues. Biochemistry 26:202-221.
24. Lawrence DA, Ginsburg D, Day DE, Berkenpas MB, Verhamme IM, Kvassman JO, Shore JD. 1995. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J Biol Chem 270:25309-25312.
25. 1-proteinase inhibitor: Crystal structure analysis of two modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol 171:531-556
26. 2-antiplasmin as a model inhibitor. Biochemistry 30:979-986.
27. 2-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry 30:1723-1730.
28. 1-proteinase inhibitor probed by limited proleolysis. Biochemistry 31:2720-2728.
29. Matsudaira P. 1987. Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. J Biol Chem 262: 10035-10038.
30. Morihara K, Oka T, Tsuzuki H. 1970. Subtilisin BPN': Kinetic study with oligopeptides. Arch Biochem Biophys 138:515-525
31. 1antichymotrypsin. J Biol Chem 258:12749-12752.
32. 1antichymotrypsin. Inflammation 19:75-81.
33. Patston PA, Gettins P, Beechem J, Schapira M. 1991. Mechanism of serpin action: Evidence that C1 inhibitor functions as a suicide substrate. Biochemistry 30:8876-8882.
34. Perona JJ, Craik CS. 1995. Structural basis of substrate specificity in the serine proteases. Protein Sci 4:337-360.
35. Rawlings N, Barrett AJ. 1994. Families of serine peptidases. Methods Enzymol 244:19-61.
36. Read RJ, James MNG. 1986. Introduction to the protein inhibitors: X-ray crystallography. In: Barrett AJ, Salvesen G, eds. Proteinase inhibitors. Amsterdam: Elsevier. pp 301-336.
37. Robertas JD, Alden RA, Birktoft JJ, Kraut J, Powers JC, Wilcox PE. 1972. An X-ray crystallographic study of the binding of peptide chloromethyl ketone inhibitors to subtilisin BPN'. Biochemistry 11:2439-2449.
38. 1,-antichymotrypsins. J Biol Chem 265:1199-1207.
39. Salvesen G, Nagase H. 1989. Inhibition of proteolytic enzymes. In: Beynon RJ, Bond JS, eds. Proteolytic enzymes: A practical approach. Oxford: IRL Press. pp 83-104.
40. 1-antichymotrypsin. J Biol Chem 268:23626-23633.
41. Schlechter NM, Sproes JL, Schoenberger OL, Lazarus GS, Cooperman BS, Rubin H. 1989. Reaction of human skin chymotrypsin-like proteinase chymase with human plasma proteinase inhibitors. J Biol Chem 264: 21308-21315.
42. Schreuder HA, de Boer B, Dijkeme R, Mulders J, Theunissen HJM, Grootenhuis DJ, Hol WGJ. 1994. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nature Struct Bioi 1:48-54.
43. Siezen RJ, de Vos WM, Leunissen XAM, Dijkstra BW. 1991. Homology modelling and protein engineering strategy of subtilases, the family of subtilisin-like serine proteinases. Protein Eng 4:719-737.
44. Stein PE, Carrell RW. 1995. What do dysfunctional serpms tell us about molecular mobility and disease? Nature Struct Biol 2:96-113
45. Takeuchi Y, Noguchi S, Satow Y, Kojima S, Kumagai I, Miura K, Nakamura KT, Mitsui Y. 1991. Molecular recognition at the active site of subtilisin BPN': Crystallographic studies using genetically engineered proteinaceous inhibitor SSI (Streptomyces subtilisin inhibitor). Protein Eng 4:501-508
46. Travis J, Salvesen G. 1983. Human plasma proteinase inhibitors. Annu Rev Biochem 52:655-709.
47. Watanabe M, Hirano A, Stenglein S, Nelson J, Thomas G, Wong TC. 1995. Engineered serine protease inhibitor prevents furin-catalyzed activation of the fusion glycoprotein and production of infectious measles virus. J Virol 69:3206-3210.
48. Wei A, Rubin H, Cooperman BS, Christianson DW. 1994. Crystal structure of an uncleaved serpin reveals the conformation of an inhibitory reactive loop. Nature Struct Biol 1:251-258.
49. Wright HT, Scarsdale JN. 1995. Structural basis for serpin inhibitory activity. Proteins Struct Funct Genet 22:210-225.